PART I . Overview We are a technology-based company with a well-established laboratory services business and a therapeutic development business. Our laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Our therapeutic development business is focused on developing product candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to ...
Q2 FY2026 — expected 2026-07-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-27 | 2025-12-31 | 0001193125-26-079169 | EDGAR | 109K words |
| 2025-02-28 | 2024-12-31 | 0000950170-25-029512 | EDGAR | — |
| 2024-02-28 | 2023-12-31 | 0000950170-24-022233 | EDGAR | — |
| 2023-02-28 | 2022-12-31 | 0000950170-23-005178 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0001564590-22-007366 | EDGAR | — |
| 2021-03-08 | 2020-12-31 | 0001564590-21-011526 | EDGAR | — |
| 2020-03-13 | 2019-12-31 | 0001564590-20-010617 | EDGAR | — |
| 2019-03-22 | 2018-12-31 | 0001564590-19-008991 | EDGAR | — |
| 2018-03-20 | 2017-12-31 | 0001564590-18-006239 | EDGAR | — |
| 2017-03-17 | 2016-12-31 | 0001564590-17-004681 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-07 | 2025-09-30 | 0001193125-25-271013 | EDGAR | 30K words |
| 2025-08-01 | 2025-06-30 | 0000950170-25-101105 | EDGAR | — |
| 2025-05-02 | 2025-03-31 | 0000950170-25-062258 | EDGAR | — |
| 2024-11-08 | 2024-09-30 | 0000950170-24-123684 | EDGAR | — |
| 2024-08-02 | 2024-06-30 | 0000950170-24-089592 | EDGAR | — |
| 2024-05-03 | 2024-03-31 | 0000950170-24-052485 | EDGAR | — |
| 2023-11-03 | 2023-09-30 | 0000950170-23-058512 | EDGAR | — |
| 2023-08-04 | 2023-06-30 | 0000950170-23-038316 | EDGAR | — |
| 2023-05-05 | 2023-03-31 | 0000950170-23-018079 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0000950170-22-022661 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0000950170-22-014856 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0000950170-22-007909 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-17 | 0001674930-26-000012 | EDGAR | 2K words |
| 2026-02-27 | 0001193125-26-079152 | EDGAR | — |
| 2025-12-22 | 0001193125-25-328747 | EDGAR | — |
| 2025-11-07 | 0001193125-25-271006 | EDGAR | — |
| 2025-10-20 | 0001193125-25-242917 | EDGAR | — |
| 2025-08-01 | 0000950170-25-101103 | EDGAR | — |
| 2025-05-15 | 0000950170-25-072676 | EDGAR | — |
| 2025-05-02 | 0000950170-25-062257 | EDGAR | — |
| 2025-02-28 | 0000950170-25-029510 | EDGAR | — |
| 2024-11-08 | 0000950170-24-123681 | EDGAR | — |
135 total filings indexed. 103 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001674930 |
| Ticker | FLGT |
| Exchange | Nasdaq |
| SIC | 8071: Services-Medical Laboratories |
| Incorporated | DE |
| Website | https://www.fulgentgenetics.com |
| Listed | 2016-09-29 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report